STOCKS TELEGRAPH

Tag: SBFM Stock

  • Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma (SBFM) Stock Soars In Pre-Market Trading

    Sunshine Biopharma, Inc. (NASDAQ: SBFM) stock saw a sharp increase after the release of its 2024 financial report. SBFM shares rose 55.50% to $3.25 as of the most recent pre-market check. On Tuesday, April 1, 2025, the company formally submitted its annual report on Form 10-K, demonstrating remarkable financial expansion.

    Initiatives for Sales Growth and Expansion

    In 2024, Sunshine Biopharma reported a significant growth in sales, reaching $34.9 million, a noteworthy 45% increase over $24.1 million in the prior year. In order to finance the growth of its sales activities, SBFM also successfully concluded an underwritten public offering, raising about $10 million in gross revenues.

    Sunshine Biopharma introduced 13 new generic prescription medications in the last year, greatly expanding its pharmaceutical offering. Nine of these were disseminated through strategic partnerships, while four were introduced under cross-licensing agreements. Additionally, Health Canada granted SBFM regulatory authority to sell NIOPEG, a NEULASTA biosimilar, enhancing its portfolio of cancer medications.

    Breakthrough Therapeutics Research

    With its discoveries published in the Journal of Medicinal Chemistry, Sunshine Biopharma also achieved significant strides in therapeutic development. In a mouse model of SARS-CoV-2 infection, the study demonstrated the sub-micromolar potency and great in vivo efficiency of Sunshine Biopharma’s new coronavirus PLpro inhibitor,

    That highlighted its exceptional efficacy and was an important milestone in the company’s continuous attempts to create novel treatments for serious illnesses is this peer-reviewed study.

    Furthermore, Sunshine Biopharma’s K1.1 mRNA Lipid Nanoparticle showed potential as a new therapeutic agent for human hepatocellular carcinoma after completing proof-of-concept animal model studies. As the third most common cause of cancer-related fatalities globally, this kind of liver cancer continues to be a serious global health problem.

    Prospects for the Future and Strategic Development

    Sunshine Biopharma is unwavering in its desire to turn a profit and further its in-house medication research initiatives. As it works to introduce new life-saving medications to the market, SBFM expects to see further growth prospects in 2025 and beyond.

  • Sunshine Biopharma (SBFM) Shares Surge Following Key Drug Launch

    Sunshine Biopharma (SBFM) Shares Surge Following Key Drug Launch

    Shares of Sunshine Biopharma, Inc. (NASDAQ: SBFM) are on a significant boost following the announcement of a new drug launch. As of the latest check, SBFM stock was priced at $3.37, reflecting its robust 13.47% increase on the US stock charts. This surge underscores investor optimism surrounding the company’s expanding portfolio and recent innovations.

    Launch of Generic Bilastine in Canada

    Nora Pharma Inc., a fully owned Canadian subsidiary of Sunshine Biopharma, has introduced the new generic prescription drug bilastine to the Canadian market. Bilastine and other second-generation antihistamines are widely known for their capacity to treat allergic rhinitis and urticaria. The generic form of Blexten, manufactured by Nora Pharma, relieves allergy symptoms in 20 mg capsules.

    As part of a thriving global industry, the Canadian market for bilastine was valued at $1.3 billion in 2023 and is projected to increase at a compound annual growth rate of 6.6% to reach $2.3 billion over the next six years. A variety of reasons, such as increased healthcare spending and knowledge of allergic problems, are supporting the market for antihistamines like Bilastine.

    Expansion in Generic Drug Market

    Bilastine marks the fourth product launched by Sunshine Biopharma in 2024, signifying the company’s growing presence in the Canadian generic drugs market. By means of well-timed product launches, SBFM is gradually increasing its market share in this profitable industry.

    Developments in the Treatment of Liver Cancer

    Sunshine Biopharma also reported encouraging outcomes from preclinical mouse model trials of their K1.1 mRNA product, which is intended to treat human hepatocellular carcinoma (HCC). Despite the availability of first- and second-line treatments, the five-year survival rate for HCC, the most common primary liver cancer, is just 18–21%.

    The company’s K1.1 mRNA technology proved capable of dose-dependently penetrating cancerous liver cells and successfully stopping their proliferation. Additional studies are underway to refine dosing and establish the therapeutic window for future applications in HCC treatment.

    With a strong drug pipeline and continued innovation, Sunshine Biopharma (SBFM) is poised to expand its market influence while addressing critical healthcare challenges. Investors remain optimistic about the company’s trajectory amid these dynamic developments.

  • Sunshine Biopharma (SBFM) Surges Amid Post-Market Bullish Rush

    Thursday proved fruitful for Sunshine Biopharma, Inc. (NASDAQ: SBFM), witnessing a commendable 6.14% uptick in its stock. Yet, the real spectacle unfolded after market closure, as the stock soared an astonishing 39.50%. Investors are ecstatic with this afterhours gain, speculating whether this momentum will persist into Monday.

    Company Overview and Financial Performance

    Sunshine Biopharma, Inc. operates in pharmaceuticals, focusing on oncology, antiviral drugs, and nutritional supplements. Recent financials depict strength, with Q4 revenue surpassing estimates by 26% at $6.1 million. Full-year 2023 revenue stands at $24.1 million, with a gross margin of 34.6% and adjusted EBITDA of $4.6 million. Interest income for the year totaled $812,000.

    Market Analysis and Investor Sentiment

    Analysts believe Sunshine Biopharma, Inc. is undervalued, foreseeing over 55% growth in drug sales by 2025. Yet, challenges loom, including a potential delisting due to a persistently low stock price. Despite efforts to rectify this, another delisting warning emerged.

    The sudden turnaround in sentiment, as reflected in the sudden price jump comes with renewed confidence that the planned stock split may actually yield results. There is a growing perception among market players that the delisting scare has brought down the price of SBFM far more than its fair price. In light of this, the stock seems to be rushed by bulls looking to make an early entrance prior to the stock’s bounce back to more normal levels.

    Future Prospects and Investor Concerns

    Management faces pressure to restore investor confidence and reverse the stock’s decline, seen earlier last month. Suggestions include focusing on generic drug profitability through divesting or spinning off drug development programs. However, doubts linger regarding management’s stake and potential leadership changes.

    Conclusion

    Sunshine Biopharma, Inc.’s rapid stock surge underscores market unpredictability, particularly in biopharmaceuticals. As the company approaches its Nasdaq Hearings Panel meeting in April, investors await developments that could restore faith in its trajectory.

  • Sunshine Biopharma Inc. (SBFM) won’t Stop Rallying on Breakthrough Cancer Treatment

    Sunshine Biopharma Inc. (SBFM) won’t Stop Rallying on Breakthrough Cancer Treatment

    Sunshine Biopharma Inc. (SBFM) recently announced a breakthrough treatment for cancer of several kinds. Immediately after the announcement, the stock made it to the top charts on multiple social media stock chats. The stock has since been capitalizing on the news, maintaining its gains it has continued rising in today’s premarket.

    Source: Cleveland Clinic

    At the last check on April 8, SBFM was rallying by a further 23.21% in the premarket after having surged by 53.42% the day before. Thus, the stock was trading at a value of $11.90 at the time of writing.

    SBFM’s Breakthrough Treatment

    On April 5, the company disclosed that two of its newly designed mRNA molecules have proven effective in killing cancer cells grown in culture. The molecules were tested on multidrug-resistant breast cancer as well as ovarian and pancreatic cancer. Moreover, the new mRNA molecules also showed positive results in toxicity studies in normal human cells with little to no cytotoxic effects. A further positive point of the molecules is their adaptability for delivery to patients through mRNA vaccine technology.

    Therefore, the company is planning to file a patent application regarding the results as soon as possible.

    A Multi-Billion Market Opportunity

    Anti-cancer discovery is a multi-billion global market opportunity. The global cancer immunotherapy market is expected to reach a value of $167.5 billion by 2027 at a CAGR of 9.10% during 2022-to 2027. Cancer is one of the leading causes of death worldwide with the number of patients growing each year. Immunotherapy involves using antibodies to treat cancer by a selective attack on cancerous cells. Given the higher number of advantages and lesser side effects, cancer immunotherapy is now becoming the dominant treatment method for cancer.

    SBFM’s Outlook

    With breakthrough cancer treatment on hand and a market opportunity that is multi-billion dollars, SBFM currently seems to be set for exponential growth. But it is easier said than done, as the road to commercialization is very long.

    Other than the new mRNAs, the company is also working on a treatment for Covid-19 while having completed the synthesis of four potential inhibitors. Furthermore, the development of another anti-cancer compound is also well underway along with collaborative clinical trials.

    Conclusion

    In conclusion, the enthusiasm and momentum generated by the cancer treatment news have the stock rallying continuously.

    While the discovery is groundbreaking and comes with a huge market, future developments and patent news are likely to solidify SBFM’s position.

  • Is This Why The SBFM Stock Rose Last Trading?

    The stock of Sunshine Biopharma Inc [OTCPK: SBFM] soared 142.00% to $0.2420 at the previous close. Volume in Sunshine Biopharma stock was 96.69M shares compared with 7.46M shares over the past 30 days. SBFM stock value fluctuated between $0.0015 and $0.3000 during the last 52 weeks. SBFM stock climbed following announcing method of actions for its anti-cancer drug candidate.

    How did that method work?

    Sunshine Biopharma focuses on researching, developing, and commercializing antiviral and oncology drugs. Currently, SBFM is developing an oral treatment for COVID-19 in the area of antiviral drugs. There is no drug that can stop the replication of the virus in sufferers.

    Yesterday, Sunshine Biopharma announced that Adva-27a, the Company’s flagship anticancer drug candidate, had been elucidated for the first time.

    SBFM’s Adva-27a inhibits two cellular processes of P-glycoprotein evasion and Topoisomerase II inhibition. Over 50% of all cancer types increase multidrug resistance by secreting P-glycoprotein.

    Due to the fact that SBFM candidate Adva-27a escapes the efflux pump of P-glycoprotein, it accumulates inside cancer cells and destroys them by inhibiting Topoisomerase II, an enzyme that is frequently employed by cancer cells for multiplication.

    Scope of SBFM’s new drug:

    Adva-27a is able to destroy both populations of cancer cells, rendering cancer treatment more successful. SBFM’s this development could have a huge impact on cancer treatment in general. In the near future, Sunshine Biopharma (SBFM) is likely to offer a new drug to cancer sufferers worldwide.